Aktionsplan Dianthus Therapeutics, Inc.
Erweiterter Zeitplan
Einfaches Diagramm
Über das Unternehmen Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.| IPO date | 2023-09-12 |
|---|---|
| ISIN | US2528281080 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://dianthustx.com |
| Цена ао | 18.27 |
| Preisänderung pro Tag: | +0.6039% (19.87) |
|---|---|
| Preisänderung pro Woche: | +2.57% (19.49) |
| Preisänderung pro Monat: | -3.01% (20.61) |
| Preisänderung über 3 Monate: | -12.09% (22.74) |
| Preisänderung über sechs Monate: | -26.99% (27.38) |
| Preisänderung pro Jahr: | -33.37% (30) |
| Preisänderung über 3 Jahre: | +11 042.7% (0.1794) |
| Preisänderung über 5 Jahre: | +2 489.71% (0.7719) |
| Preisänderung seit Jahresbeginn: | -16.04% (23.81) |
|
|
Unterschätzung
|
Effizienz
|
|||||||||||||||||||||||||||||||||||||
Dividenden
|
Pflicht
|
Wachstumsimpuls
|
|||||||||||||||||||||||||||||||||||||
| ETF | Aktie, % | Rentabilität für das Jahr, % | Dividenden, % |
|---|---|---|---|
| iShares Morningstar Small-Cap Growth ETF | 0.01576 | 572.1 | 0.72598 |
| iShares Morningstar Small-Cap ETF | 0.00782 | 391.25 | 1.60498 |
| 0.01 | 481.68 | 1.17 |
| Aufsicht | Berufsbezeichnung | Zahlung | Geburtsjahr |
|---|---|---|---|
| Mr. Marino Garcia M.B.A. | President, CEO, Secretary & Director | 1966 (59 Jahre) | |
| Mr. Ryan Savitz | CFO and Chief Business Officer & Treasurer | 1989 (36 Jahre) | |
| Mr. Simrat Randhawa M.B.A., M.D. | Chief Medical Officer | 1970 (55 Jahre) | |
| Mr. Edward G. Carr | Chief Accounting Officer | 1969 (56 Jahre) | |
| Mr. Judson Taylor | Head of Technical Operations | ||
| Dr. Jeffrey Stavenhagen Ph.D. | Chief Scientific Officer | ||
| Ms. Jennifer Davis Ruff | VP and Head of Investor Relations & Corporate Affairs. | ||
| Mr. Adam M. Veness Esq. | Senior VP, General Counsel & Secretary | 1986 (39 Jahre) | |
| Ms. Kristina Maximenko | Chief People Officer | ||
| Ms. Rashieda Gluck | Head of Clinical Development Operations |
Adresse: United States, New York, 7 Times Square - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://dianthustx.com
Webseite: https://dianthustx.com
